aflibercept sold brand names eylea among others medication used treat wet macular degeneration metastatic colorectal cancer developed regeneron pharmaceuticals approved united states european inhibitor vascular endothelial growth factor aflibercept eylea indicated treatment people neovascular wet agerelated macular degeneration macular edema following retinal vein occlusion diabetic macular edema diabetic retinopathy retinopathy aflibercept zaltrap combination fluorouracil leucovorin irinotecan folfiri indicated treatment people metastatic colorectal cancer resistant progressed following oxaliplatincontaining used treatment wet macular degeneration administered intravitreal injection cancer treatment given intravenously combination fluorouracil leucovorin irinotecan august aflibercept eylea approved treatment people visual impairment due diabetic macular edema according updated summary product may us fda expanded indication aflibercept include stages diabetic february us fda approved aflibercept eylea treatment retinopathy aflibercept eylea contraindicated people infections active inflammations near aflibercept zaltrap common adverse effects eye formulation include conjunctival hemorrhage eye pain cataract vitreous detachment floaters ocular aflibercept zaltrap adverse effects typical anticancer drugs reduced blood cell count leukopenia neutropenia thrombocytopenia gastrointestinal disorders like diarrhea abdominal pain fatigue another common effect hypertension increased blood interactions described either wet macular degeneration abnormal blood vessels grow choriocapillaris layer capillaries eye leading blood protein leakage macula aflibercept zaltrap binds circulating vegfs acts like vegf thereby inhibits activity vascular endothelial growth factor subtypes vegfa vegfb well placental growth factor pgf inhibiting growth new blood vessels choriocapillaris tumour aim cancer treatment speak starve tumour aflibercept recombinant fusion protein consisting vascular endothelial growth factor vegfbinding portions extracellular domains human vegf receptors fused fc portion human regeneron commenced clinical testing aflibercept cancer regeneron signed major deal aventis develop aflibercept field regeneron started testing compound locally delivered proliferative eye regeneron bayer signed agreement develop eye november united states food drug administration fda approved aflibercept treatment wet macular august us fda approved aflibercept zaltrap use combination folinic acid irinotecan treat adults metastatic colorectal cancer resistant progressed following avoid confusion version injected eye fda assigned new name zivaflibercept active november european medicines agency ema approved aflibercept eylea treatment wet macular february european medicines agency ema approved aflibercept zaltrap treatment adults metastatic colorectal cancer treatment based oxaliplatin worked cancer got aflibercept zaltrap used folfiri treatment combining medicines irinotecan folinic march aflibercept one group drugs delisted uk cancer drugs injections aflibercept hcpcs code responsible billing medicare part b march regeneron reported aflibercept failed primary endpoint overall survival vital phase iii trial secondline treatment locally advanced metastatic nonsmall cell lung cancer nsclc although improved secondary endpoint progressionfree april regeneron reported aflibercept improved primary endpoint overall survival velour phase iii clinical trial secondline treatment metastatic colorectal cancer aflibercept also phase iii trial hormonerefractory metastatic prostate cancer april cochrane review examined outcomes comparing aflibercept versus ranibizumab injections people neovascular amd two randomized controlled trials treatment options yielded similar improvements visual acuity morphological outcomes though authors note aflibercept treatment regimen potential reduce treatment burden risks frequent review update studying effects antivegf drugs diabetic macular edema found three studied treatments advantages laser therapy moderate evidence aflibercept significantly favored measured efficacy outcomes ranibizumab bevacizumab one httpsenwikipediaorgwikiaflibercept